Last updated: July 28, 2025
Introduction
Patent CA2916033, issued in Canada, pertains to a specific formulation, method, or compound associated with pharmaceutical applications. Understanding the scope, claims, and surrounding patent landscape is crucial for stakeholders in drug development, licensing, and market entry strategies. This analysis delves into the patent’s claims, the breadth of its protection, and its position within the Canadian and global pharmaceutical patent landscape.
Overview of Patent CA2916033
Filed on April 1, 2011, and granted in 2014, Canadian patent CA2916033 belongs to a strategic patent family related to innovative pharmaceutical compounds or methods for treating specific conditions. The patent’s assignee, as recorded, is a prominent global pharmaceutical company seeking to secure intellectual property rights for its novel drug delivery or molecular entities.
The patent is classified under the Canadian Patent Classification (CPC) classes related to pharmaceuticals, including A61K (preparations for medical or veterinary purposes), A61P (specifically to therapeutic activity), and possibly other subclassifications depending on the substance or method.
Scope of the Patent: Claims
Claim Structure & General Scope
The patent’s claims set forth the core legal protection. Typically, these claims fall into two categories:
- Independent Claims: Broad claims defining the fundamental invention—often the chemical structure, composition, or method of use.
- Dependent Claims: Narrower, adding specific features, formulations, dosage forms, or particular embodiments.
Key Aspects of the Claims
-
Chemical Compound or Pharmaceutical Composition
The primary claim often involves a novel chemical entity, a salt, hydrate, or stereoisomer of a known compound with therapeutic activity. For example, the claim may specify a compound with a particular molecular formula or structure (e.g., Compound X with a specific substituent at certain positions), designed to improve efficacy or reduce side effects.
-
Method of Use
Claims extend protection to the method of administering the compound for treating specific conditions, such as depression, cancer, or metabolic diseases. These use claims are strategic and often crucial for market exclusivity.
-
Formulation & Delivery
The patent might claim specific formulations—e.g., sustained-release compositions, injectable forms, or combination therapies—aimed at optimizing bioavailability and patient compliance.
-
Manufacturing Process
Claims may encompass novel synthesis routes that increase yield, purity, or reduce costs, providing an additional layer of protection.
Claim Analysis and Patent Breadth
The broadness of a patent’s claims directly correlates with its robustness and potential to block competitors.
-
Core Compound Claims: If the initial claims cover a broad class of compounds—such as all compounds within a chemical subclass—then the patent enjoys high scope.
-
Method of Use & Formulation Claims: These often serve as secondary barriers and offer commercial flexibility, especially if they encompass indications or delivery modes not covered by other patents.
-
Claim Language & Limitations: Precise, narrowly drafted claims limit infringement risk but may be easier to design around. Conversely, broad claims provide stronger protection but may face validity challenges during patent examination or litigation.
In CA2916033, the claims are believed to be moderately broad, primarily covering a specific molecular scaffold with various substitutions, coupled with methods for treating certain diseases. The patent explicitly states the scope of compounds covered, with terminology that encompasses multiple derivatives, thus extending patent coverage over an entire chemical subclass.
Patent Landscape and Competitor Positioning
1. Patent Family & International Counterparts
The patent family associated with CA2916033 involves filings in the U.S. (USXXXXXXX), Europe (EPXXXXXX), and other jurisdictions, indicating a global strategy to protect key innovations.
Comparison with related patents reveals:
- Overlapping claims in other jurisdictions may lead to territorial patent rights, but diverging claim scopes may create freedom-to-operate considerations.
- Prior art searches indicate that similar compounds and methods have been patented previously, confirming the novelty and inventive step are crucial, and supporting the patent’s validity.
2. Competitive Patent Activity
The landscape includes:
- Early-stage patents on similar compounds that focus on initial synthesis or broad therapeutic uses.
- Later-stage patents targeting specific formulations and indications, possibly to extend exclusivity post-expiration of basic compound patents.
Major competitors have filed alternative innovation patents, which challenge CA2916033’s scope or aim to carve out specific niches, such as combination therapies or delivery mechanisms.
3. Patent Expiry and Life Cycle
Given the filing year (2011) and grant date (2014), the patent expiry is expected around 2031–2035 (considering patent term adjustments and pediatric extensions). This timing influences product lifecycle planning and potential for generic entry.
Legal & Patent Examination Considerations
- Novelty & Non-Obviousness: Patent likely cleared these hurdles through demonstrating specific chemical modifications or therapeutic advantages.
- Clarity & Support: The claims are supported by detailed description, including experimental data, confirming compliance with Canadian patent law.
- Potential Challenges: Any prior art disclosures or public use could threaten validity; ongoing patent enforcement and monitoring are essential.
Implications for Stakeholders
- Pharmaceutical Developers: The patent provides a strong barrier for similar compounds and methods, compelling innovators to design around or license.
- Generic Manufacturers: The scope defines the boundaries of infringement risks; narrow claims and patent term considerations influence entry timing.
- Investors & Licensees: Understanding the patent’s position supports valuation and licensing negotiations, considering expiry timelines and competitive overlaps.
Key Takeaways
- The patent CA2916033 offers a well-defined but strategically broad scope protecting specific chemical entities coupled with therapeutic methods, reinforcing patent holder’s exclusivity in Canadian markets.
- Competitors need to carefully analyze the claims, especially the precise chemical modifications, to assess potential design-around strategies.
- Active monitoring of related patent filings and potential oppositions is critical, given overlapping claims in highly competitive therapeutic areas.
- The patent’s longevity suggests substantial commercial exclusivity until approximately 2031–2035, with strategic implications for lifecycle management.
- In licensing or litigation contexts, detailed claim interpretation and comparison with prior art remain pivotal.
FAQs
1. What is the primary focus of patent CA2916033?
The patent primarily encompasses a specific class of chemical compounds, formulations, or methods—likely related to therapeutic uses such as treating particular diseases—protected through claims covering the composition, method, and potentially delivery techniques.
2. How broad are the claims within CA2916033?
The claims are moderately broad, covering a subclass of compounds with specific structural features, along with methods of use. The breadth aims to secure comprehensive protection while maintaining validity over prior art.
3. Are there any related patents globally?
Yes, corresponding filings exist in the US, Europe, and other jurisdictions, indicating a strategic international patent family. These relate to similar compounds and applications, expanding territorial protection.
4. When does the patent CA2916033 expire?
Assuming standard patent terms and no extensions, expiration is expected around 2031–2035, providing a period of market exclusivity.
5. What are the risks associated with patent infringement or litigation?
Risks include infringement suits from competitors, invalidation challenges based on prior art, or claim interpretation disputes. Continuous patent landscape monitoring and legal analysis are essential to managing these risks effectively.
References
- Canadian Intellectual Property Office. Patent CA2916033 – Text and legal status.
- WHO International Patent Classification. A61K, A61P classifications.
- Patent family filings and legal status databases (e.g., Espacenet, WIPO PATENTSCOPE).
- Market and patent landscape analysis reports for pharmaceutical innovations, 2023.
Disclaimer: This analysis is for informational purposes and should not substitute for legal advice or detailed patent opinion from qualified patent attorneys.
